Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$28.0 - $40.56 $40,656 - $58,893
-1,452 Reduced 6.83%
19,821 $803,000
Q3 2022

Nov 14, 2022

SELL
$29.63 - $48.31 $9,066 - $14,782
-306 Reduced 1.42%
21,273 $703,000
Q2 2022

Aug 15, 2022

SELL
$27.79 - $50.61 $9,393 - $17,106
-338 Reduced 1.54%
21,579 $760,000
Q1 2022

May 13, 2022

SELL
$39.62 - $69.97 $31,339 - $55,346
-791 Reduced 3.48%
21,917 $1.01 Million
Q4 2021

Feb 14, 2022

SELL
$58.09 - $82.51 $8,423 - $11,963
-145 Reduced 0.63%
22,708 $1.51 Million
Q3 2021

Nov 15, 2021

SELL
$58.38 - $84.96 $4,845 - $7,051
-83 Reduced 0.36%
22,853 $1.43 Million
Q2 2021

Aug 13, 2021

BUY
$62.15 - $90.32 $23,368 - $33,960
376 Added 1.67%
22,936 $1.9 Million
Q1 2021

May 14, 2021

BUY
$61.35 - $90.47 $10,858 - $16,013
177 Added 0.79%
22,560 $1.5 Million
Q4 2020

Feb 12, 2021

SELL
$43.82 - $85.37 $3,637 - $7,085
-83 Reduced 0.37%
22,383 $1.72 Million
Q3 2020

Nov 16, 2020

BUY
$33.21 - $51.27 $25,405 - $39,221
765 Added 3.53%
22,466 $967,000
Q2 2020

Aug 14, 2020

SELL
$26.12 - $43.27 $44,717 - $74,078
-1,712 Reduced 7.31%
21,701 $937,000
Q1 2020

May 14, 2020

SELL
$20.56 - $63.12 $11,554 - $35,473
-562 Reduced 2.34%
23,413 $675,000
Q4 2019

Feb 13, 2020

SELL
$28.14 - $73.01 $2,617 - $6,789
-93 Reduced 0.39%
23,975 $1.52 Million
Q3 2019

Nov 13, 2019

SELL
$26.26 - $34.86 $577 - $766
-22 Reduced 0.09%
24,068 $678,000
Q2 2019

Aug 14, 2019

SELL
$17.43 - $28.82 $6,588 - $10,893
-378 Reduced 1.54%
24,090 $641,000
Q1 2019

May 14, 2019

SELL
$12.05 - $20.18 $2,747 - $4,601
-228 Reduced 0.92%
24,468 $450,000
Q4 2018

Feb 13, 2019

BUY
$10.74 - $19.7 $265,235 - $486,511
24,696 New
24,696 $306,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.